『The Biorevolution Podcast』のカバーアート

The Biorevolution Podcast

The Biorevolution Podcast

著者： Louise von Stechow
無料で聴く

The Biorevolution Podcast with Andreas Horchler and Louise von Stechow – father and daughter, journalist and biologist, talking about the technologies of the biorevolution. Can genetic engineering, synthetic biology, and artificial intelligence save humanity from disease, climate change, and overpopulation, or are these technologies the first step towards its downfall? Content and Editing: Louise von Stechow and Andreas Horchler Disclaimer: Louise von Stechow, Andreas Horchler and their guests express their personal opinions, which are founded on research on the respective topics but do not claim to give medical, investment, or life advice in the podcast. Learn more about the future of biotech in our podcasts and keynotes. Contact us here: scientific communication: https://science-tales.com/ Podcasts: https://www.podcon.de/ Image: Kelly Sikkema via Unsplash 博物学 生物科学 科学 自然・生態学
エピソード
  • Nature’s origami– DNA nanotechnology

    Nature’s origami– DNA nanotechnology
    2026/05/21
    DNA nanotechnology treats DNA not primarily as a carrier of genetic information, but as a programmable material. Based on the predictability of Watson–Crick base pairing, DNA nanotechnology allows researchers to encode specific structural information. DNA origami, in particular, is an interesting approach for reproducibly folding complex two- and three-dimensional DNA nano-objects. The potential of DNA origami structures shows their versatility, from biosensing and diagnostics to drug delivery, biomaterials, DNA data storage, and computing — even though the field is still at a comparatively early stage, with a number of interesting biotechs emerging. With DNA nanotechnology expert and science writer Marco Lolaico, we discuss the fascinating field of DNA nanotechnology, with structures from DNA smileys to DNA bunnies, to movable DNA machines. We ask Marco how big “huge” is through a nanotech lens, and whether we can expect a Nobel Prize for the technology. Find Marco here: https://www.linkedin.com/in/marco-lolaico/ Find his “Plenty of room” newsletter here: https://plentyofroom.beehiiv.com/ Disclaimer: Louise von Stechow & Andreas Horchler and their guests express their personal opinions, which are founded on research on the respective topics, but do not claim to give medical, investment or even life advice in the podcast. References: 1. Nature Research Intelligence DNA Nanotechnology and Biomedical Applications. https://www.nature.com/research-intelligence/nri-topic-summaries/dna-nanotechnology-and-biomedical-applications-micro-2491 2. Seeman NC. Nucleic acid junctions and lattices. 1982. https://ui.adsabs.harvard.edu/link_gateway/1982JThBi..99..237S/doi:10.1016/0022-5193(82)90002-9 3. Rothemund PWK. Folding DNA to create nanoscale shapes and patterns. 2006. https://ui.adsabs.harvard.edu/link_gateway/2006Natur.440..297R/doi:10.1038/nature04586 4. Seeman NC, Sleiman HF. DNA nanotechnology. 2017. https://www.nature.com/articles/natrevmats201768 5. Zhan P et al. Recent Advances in DNA Origami-Engineered Nanomaterials. 2023. https://pubs.acs.org/doi/10.1021/acs.chemrev.3c00028 6. Dunn KE. The Business of DNA Nanotechnology: Commercialization of Origami and Other Technologies. 2020. https://www.mdpi.com/1420-3049/25/2/377 7. https://plentyofroom.beehiiv.com/p/molecular-hard-drives-dna-origami-rewrites-data-storage 8. Zhang C. Linked data storage using DNA origami nanostructures. 2025. https://www.nature.com/articles/s41467-025-66274-x 9. https://plentyofroom.beehiiv.com/p/dna-origami-boosts-anti-hiv-antibodies-vaccine-breakthrough 10. Romanov A. DNA origami vaccines program antigen-focused germinal centers. 2026. https://www.science.org/doi/10.1126/science.adx6291
    続きを読む 一部表示
    35 分
  • From biohacking to healthcare- the growing pains of the longevity industry

    From biohacking to healthcare- the growing pains of the longevity industry
    2026/05/04
    From Biohacking to Healthcare- the growing pain of the Longevity Industry Shownotes the BioRevolution podcast episode 48 For most of human history, “living longer” mainly meant not dying early but this has changed drastically with significantly increased life expectancy in the 20th century. This raises a new question: how can we live longer, individually and as a society, without simply shifting the burden into more years lived with chronic disease? Researchers are increasingly reframing the problem away from purely disease-by-disease fixes and toward the underlying biology of ageing that contributes to multiple conditions, such as cancer, cardiovascular, neurodegenerative, and metabolic disease. While the field is only beginning to untangle the complex, and likely multifactorial process of aging, a fledgling longevity industry has emerged around various hypotheses of aging mechanisms. The longevity industry spans therapeutics that target ageing-linked mechanisms, biomarkers and “clocks” that aim to measure biological ageing, and delivery models (clinics, digital platforms, consulting) that package measurement and interventions into services. In episode 48 of the BioRevolution podcast, we talk to Niko Hems, Growth Lead of Berlin-based longevity company YEARS and longevity writer and podcaster. Find Niko here: https://www.linkedin.com/in/niko-hems/ Find Niko’s “Beyond the Hype” course here: https://beyondthehype.kit.com/niko Find Niko’s podcast “Return on Health” with Miguel Medina here: https://open.spotify.com/show/3UmkL9XmmCGIs3jrxSV9CY?si=a74386952a2940f8 Find YEARS here: https://www.years.co/de Disclaimer: Louise von Stechow & Andreas Horchler and their guests express their personal opinions, which are founded on research on the respective topics, but do not claim to give medical, investment or even life advice in the podcast. Learn more about the future of biotech in our podcasts and keynotes. Contact us here: scientific communication: https://science-tales.com/ Podcasts: https://www.podcon.de/ Keynotes: https://www.zukunftsinstitut.de/louise-von-stechow Sources 1. https://ourworldindata.org/data-insights/global-average-life-expectancy-has-more-than-doubled-since-1900 2. https://www.nature.com/articles/s43587-024-00702-3 3. https://pubmed.ncbi.nlm.nih.gov/39418098/ 4. https://pubmed.ncbi.nlm.nih.gov/36599349/ 5. https://pubmed.ncbi.nlm.nih.gov/37118377/ 6. https://pharmaphorum.com/news/billionaire-backed-rejuvenation-start-up-altos-labs-launches-operations 7. https://blog.newlimit.com/p/newlimit-raises-130-million-series 8. https://pulse24.ai/news/2025/8/22/20/ai-boosts-cell-rejuvenation 9. https://www.biopharmatrend.com/news/fda-greenlights-first-human-trial-of-epigenetic-rejuvenation-therapy-for-vision-loss-1483/ 10. https://shiftbioscience.com/shift-bioscience-raises-16m-to-advance-ai-virtual-cell-platform-for-cell-rejuvenation/ 11. https://clock.bio/ 12. https://pubmed.ncbi.nlm.nih.gov/40563501/ 13. https://www.pharmiweb.com/press-release/2025-09-17/rubedo-life-sciences-announces-us-fda-clearance-of-ind-for-selective-gpx4-modulating-lead-drug-can 14. https://longevity.technology/news/senisca-raises-3-7-million-for-rapid-development-of-senotherapeutic-platform/ 15. https://dogagingproject.org/ 16. https://www.nature.com/articles/s41587-025-02932-1 17. https://link.springer.com/rwe/10.1007/978-3-030-22009-9_400 18. https://www.businesswire.com/news/home/20251216261885/en/Aeovian-Pharmaceuticals-Raises-%2455-Million-to-Advance-First-in-Class-Selective-mTORC1-Inhibitor-for-Tuberous-Sclerosis-Complex-Related-Epilepsy 19. https://pubmed.ncbi.nlm.nih.gov/34425083/ 20. https://www.biospace.com/press-releases/novo-nordisk-a-s-evoke-phase-3-trials-did-not-demonstrate-a-statistically-significant-reduction-in-alzheimers-disease-progression 21. https://pubmed.ncbi.nlm.nih.gov/37179335/ 22. https://www.businesswire.com/news/home/20250111808660/en/Immunis-Closes-%2425-Million-Series-A-1-Financing-Round
    続きを読む 一部表示
    37 分
  • AI driven protein design- beyond nature's blueprint

    AI driven protein design- beyond nature's blueprint
    2026/04/20
    Nature has “gifted” us proteins that carry out a vast array of functions in cells, shaping the lives of all organisms, ecosystems, and ultimately the planet. In the age of synthetic biology, researchers are pushing beyond the catalogue of naturally evolved proteins by redesigning or even de novo designing proteins to make them more suitable for human goals—improving function, stability, specificity, manufacturability, or even creating entirely new capabilities. Artificial intelligence is becoming an important ally in transforming protein engineering from a trial-and-error process into a more predictive discipline, where deep learning models help predict the structure and function of a novel protein directly from its sequence. This enables faster generation and optimization of sequences for desired functions and reduces expensive and time-consuming wet-lab cycles. In this episode of the BioRevolution Podcast, Louise von Stechow and Andreas Horchler speak with Ingmar Schuster, AI expert and CEO of the protein design company Provolut, about the hopes, myths, and real potential of AI in protein design. Find Imgmar here: https://www.linkedin.com/in/ingmar-schuster/ Find Provolut here: https://provolut.bio/ Learn more about how they approach protein design for their clients here:https://provolut.bio/case-study-max-planck-insitute/ Disclaimer: Louise von Stechow & Andreas Horchler and their guests express their personal opinions, which are founded on research on the respective topics, but do not claim to give medical, investment or even life advice in the podcast. Sources 1. https://www.sciencedirect.com/science/article/pii/S2590093525000177 2. https://www.nature.com/articles/s44222-025-00349-8 3. https://link.springer.com/article/10.1007/s11427-024-2906-3 4. https://pubs.acs.org/doi/10.1021/acscentsci.3c01275 5. https://www.nature.com/articles/s41586-021-03819-2 6. https://www.nature.com/articles/s41587-024-02211-5 7. https://www.science.org/doi/10.1126/science.add2187 8. https://www.nature.com/articles/s41587-024-02123-4 9. https://pubmed.ncbi.nlm.nih.gov/36702895/ 10. https://www.profluent.bio/platform 11. https://provolut.bio/case-study-max-planck-insitute/ 12. https://provolut.bio/provolut-partners-with-ginkgo-bioworks/ 13. https://biopharma.ginkgo.bio/resources/blog/ginkgo-technology-network-launches-providing-an-integrated-rd-experience-with-capabilities-from-over-25-inaugural-partners
    続きを読む 一部表示
    34 分
adbl_web_anon_alc_button_suppression_t1
まだレビューはありません